To read more - Taxpayers Against Fraud Education Fund

THE NATIONAL
THIS WEEK
FEBRUARY 7. 2011
(cDNLJ.COM
~
legalTtrres
Check out exclusive
daily news coverage,
blogs, videos and more
at our Web site.
&
An ALM publication
A whistleblower
and its 'pit bull'
Ven-A-Care and lawyer James Breen are
scoring major wins in False Claims Act cases.
BY DAVID BARIO
Most law finns would rush to trumpet the kind of victories
that Georgia attomey James Breen and his whistle blower client,
Ven-A-Care of the Florida Keys Inc., have scored in recent weeks.
In December, Texas and the
federal govemment announced
$766 million in Medicare and
Medicaid fraud settlements in
cases brought by Ven-A-Care.
Ven-A-CaIe's share of those settlements? $155 rnillion. On Feb.
1. a Texas jury awarded the state
$170 million in the first Ven-ACare case ever to reach trial.
Breen never even issued a press release. His one~lawyer firm,
The Breen Law Finn, based in the Atlanta suburb of AJpharetta,
doesn't even have a working Web site.
SEE VEN·A-CARE, PAGE 4
NTP faces crucial
patent challenge
Big winner in BlackBerry case is contesting
adverse findings by patent appeals board.
BY SHERI QUAlTERS
The Son Also Rises
Child of a solicitor general, clerk for Justice Samuel Alito,
Utah's new senator, Republican Mike Lee, has a sterling D.C.
legal pedigree-and a devoted Tea Party following. PAGE 15
NTP Inc. followed the massive $612.5 rnillion settlement of its
patent infringement case against BlackBerry maker Research in
Motion Ltd. in 2006 with 13 new infringement lawsuits against
technology giants. In each of these cases, the company claims
infringement of its patents related to delivering electronic mail
over wireless communications systems.
But a sticky patent law question is holding them up. At issue
is a collision between federal court rulings on patentability
and the patent Ie-examination process that takes place in the
SH NTP, PAGE 6
661T CUTS COSTS FOR US AND OUR CLIENTS
LIKE NEVER BEFORE."
KATHRYN CONDE, PARTNER, NUITER McCLENNEN & FISH LLP, BOSTON
Corporate clients now expect their law firms to run as efficiently as they do. That's why Kathryn says
WestlawNext'~ is a "no-brainer." It makes legal research much more efficient, which not only saves the
firm money, but aLso saves their dients money.
IIOll9lJ1o 8£,SZ
ZO,Z-oZOOI AN }lHOA M3N
, 1. 3f\V HlS OZ9
)l31Nl3€> II )l3IJ0U3€>
OZ9
6LOAn
Hear more at WestlawNext.coni. Learn more about Nutter at Nutter.com.
WestlawNext'"
1•
THE NATIONAL LAW JOURNAlIWWW.NU.CDM I FEBRUARY 7. 2011
Flurry of wins for whistleblower
YEN·HARE, FROM PAGE 1
I
ut
,'t
Iy
5e
,,no
(
;?
ts
5.
Yet Breen represents the most successful whistleblower ever to file suit under
the False Claims Act (PCA). Ven-A-Care
is Breen's only client, and litigating FCA
cases is Ven-A-Care's business. The PCA
allows private plaintiffs to sue on behalf
of the government; thanks to amendments to the federal law in 1986 and
the adoption of similar laws by states,
whistleblowers can receive 15% to 30%
of government settlements or judgments
in PCA cases.
Since 2000, Ven-A-Care's cases have
recovered close to $2.5 billion for state
and federal governments-far more than
any other whistleblower. The settlements
represent nearly 10% of federal recoveries in FCA cases since 1987, according to
Department of Justice statistics.
Ven-A-Care's total spoils as a "qui tam
relator" under the FCA are more than
$340 million. According to qui tam lawyers, whistleblower firms typically take
home a 40% contingent fee when their
clients are successful. (Ven-A-Care didn't
respond to interview requests and Breen
wouldn't discuss fees.)
Among the whistleblower plaintiffs'
bar, Breen has achieved cult status. His
aggressive approach to False Claims Act
litigation has inspired other lawyers
and helped drive the trend toward ever
more complex suits-and bigger recoveries. "Jim Breen is an American pit bull,"
said Patrick Bums, who advises whistleblowers and handles communications for
Taxpayers Against Fraud, a Paise Claims
Act advocacy group. "He is smart and
loving and clear-eyed and you hope to
God he's not against you."
FIGHTING IN FLORIDA
; it,
r, it
(er,
h-
nd
9
, it,
n
~er,
=nt
I
'P
ld
Technically, Ven-A-Care is a pharmacy.
It has a license to dispense drugs and an
office on touristy Duval Street in Key
West, Fla. Before the early 1990s, VenA-Care's four partners, Zachary Bentley,
T. Mark Jones, luis Cabo and John
lockwood, made a good living providing
blood-infusion therapy to cancer patients
and the elderly.
The transformation of Ven-A-Care's
business to full-time litigation began in
1990, when Bentley received a Medicare
reimbursement check for $56 for a chemotherapy drug that cost the pharmacy
$10. As Bentley later testified before a
congressional subcOmmittee, he attempted to return the check, only to learn the
amount was based on the price the drug's
manufacturer reported to the state.
The following year, the kidney dialysis
giant National Medical Care opened an
infusion clinic in Key West, nearly driving
Ven-A-Care out of business. Breen, along
with his then-partner, Atlee Wampler III,
sued NMC under the False Claims Act
in 1994, accusing it of bilking Medicare
out of millions of dollars for unnecessary
treaunents.
It was around 2 a.m. during a marathon meeting on the NMC litigation that
Ven-A-Care's assault on the drug industry
was born, Wampler said. "Mark Jones
said, 'if you think this [NMC fraud] is
bad, let me tell you about this false price
reporting scheme: " Wampler recalled. "J
don't think anybody slept until we were
able to get all that down
on paper and begin to
develop a case:
A few months later, in
June 1995, Ven-A-Care
filed suit against 20 companies in Miami federal
district court for allegedly defrauding Medicare
and Medicaid by inflating
"average wholesale prices"
for drugs. Over the next
decade, Breen followed
up with a steady stream
of suits-the true number
is unknown since many
are sealed- r epeating
nearly identical allegations
against more defendants.
Average wholesale price
is a benchmark that drug
companies report to insurers, including Medicare
and Medicaid. Ven-A-Care
claimed that generic drug
companies were inflating
average wholesale prices
in order to market the
"spread" between reported prices and the amount
their wholesale customers
actually paid. The pharmades allegedly paid one
price, received outsized
reimbursements from the
government and pocketed
the difference.
Ven-A-Care's efforts
began to bear fruit in PATRICK O'CONNELL: The Texas lawyer said Ven-A-Care's and Breen's "gen ius
2000, when National was realizing they need to help the government."
Medical Care (now FreOnly a handful of states had false claims
senius Medical Care) settled its case for
$486 million. The following year, Bayer
statutes when Breen began working with
the Texas attorney general's office in 1999.
A.G. became the first to settle averageBut by the time Texas intervened in Venwholesale-price claims; since then, at
A-Care cases and began reaching settleleast II companies, including Abbott
laboratories, Aventis (now Sanofiments in 2003, other states had taken
Aventis), Bristol-Myers Squibb Co. and
notice. Qui tam lawyer Daniel Miller of
Berger & Montague, a fonner Delaware
Teva Phannaceutical Industries Ltd., have
deputy attorney general and past president
reached $100 million-plus settlements
of the National Association of Medicaid
in Ven-A-Care FCA cases. According
Fraud Control Units, said those early Vento health care fraud experts, the cases
helped convince legislators to reform
A-Care successes in Texas helped inspire
price-reporting standards and prevented
other states to adopt false claims statutes,
bringing the number of states with sintilar
massive losses to Medicare and Medicaid.
laws to 28 today. (MJller's partners curDETAILED KNOWLEDGE
rently represent Ven-A-Care.)
Patrick O'Connell, who lirigated VenWhat's the secret to Ven-A-Care's success? To start, it had detailed knowledge
A-Care cases in Texas as former chief of
of the industry, access to drug-pricing data
the state AG's Medicaid fraud section,
and, by all accounts, plenty of outrage.
said Breen understood he had to do more
(The Ven-A-Care parmers pestered offithan just file suit and hope for state and
dals from the Depamnent of Health and
federal prosecutors to take action.
Human Services and the Federal Bureau
"Their genius was realizing they need
to help the government, not just rush in
of Investigation, among others, before
turning to the courts over drug pricing.)
and say, 'take this case.' " said O'Connell,
Ven-A-Care also had timing on its side: By
now a private whistleblower lawyer at
Austin, Texas-based O'Connell & Soifer.
targeting so much of the industry early on,
it earned "first-to-file" status in much of
And, O'Connell said, "they were willing
the drug-pricing whistleblower litigation.
to commit resources."
But according to whistJeblower lawyers,
One former state prosecutor, who
Breen also helped pioneer a new approach
requested anonymity because his finn is
involved in drug-pricing cases, said few
to the False Claims Act. He brought highly developed cases, backed by enough
whistleblowers remain active litigants in
legal muscle to present Ven-A-Care as a
FCA cases once prosecutors intervene.
The Ven-A-Care whistleblowers are an
viable partner to prosecutors. And early
exception, he said, partly because they've
on, Breen pressed his cases with state
proven they can pull their own weight.
attorneys general, with results that have
SEE YEN·HARE, PAGE 5
reached beyond the drug-pricing litigation.
THENATIONAL LAW JOURNAlIWWW.
IAWJOU
Having recently expanded into
is seeking to further expand or
Minneapolis, Ohio and New Yo
level lateral attorneys with pan
areas: Labor & Employment, C.
Estate, Banking, Bankruptcy, Pr,
Compliance, and Corporate Tra
business need apply.
Headquartered in Chicago, S
attorneys based in six offices in
attorneys regularly practice in
Wisconsin and Missouri in hOI
our attorneys are retained on a
to handle both coordinating c(
representation of clients in oth,
Please submit your resume in
or by mail to:
Michael 1. Delargy
SmithAmundsen llC
150 N. Michigan Avenue,
Suite 3300
Chicago, IL 6060 1
MERRILL LAD
Clients worldwide rely on Merrill LA[
manage the complex litigation lifecyclt
to trial. Our deposition services indu.
realtime deposition reporters, realtim
Lextranet®Transcript Repository, traJ
Certified Legal Video Specialists. videc
free deposition suites, and online SChE
THE NATIONAL LAW JOURNAUWWW.NU.COMIFEBRUARY 7. 2011
5
NATIONAL NEWS I
... -.. ....
,
Ven-A-Care's $100 million-plus False Claims Act settlements
--- - -- -- - - - - - -- - - -- - --"-"-- - ----- ~ - --- --- - --- -- - - - ---- -- -- - --- --------- ----------- . --------.---.----.---------- ------------------- - - - - - - - ----- -- --
•
,I
,,
It'dlf,jk'J!! I
J"ijitWn,'l i.1
i,.g"MJI'J! fi
FreseniusMedical Care of North America
GlaxoSmithKline
Aventis Pharmaceuticals Inc.
s.ttItment
Setttement
Settlement
Sl90million
S486million
Ven-A-<are award
$150 million
Ven-A-Ca.. _
.. ----------- -- -- -
- - - - - -- - -
.
IDDIm
I
"From the very beginning, we've seen
it as our job to augment the litigation
resources that the U.S. attorneys or the
state AGs have," Breen said. "That means
assembling teams of private lawyers,
training the AGs, assisting them in the
nuts and bolts of how to develop strategy
for complex national litigation."
It's also meant investing huge sums
in litigation that, at least for a few years,
appeared uncertain. Breen said Ven-ACare's successes so far have required
more than 100,000 hours of lawyer time,
- -- - - - - -- -- - - - - - - - - - - - - - - - - - - - -
5124 million
Yen-A-Careaward
S10.8 million
- - - - - -- - - - - - - - - - - - -
Dey InclOey Pharma
Settlement
5280 mlllion
Yen-A-Care award
$67.2 million
with a value of well more than $60 million at market rates. To keep up with
cases in Florida, California and Texas and
in ongoing multidistrict litigation in federal court in Boston, Breen has had to
counter an army of defense lawyers with
an army of his own.
All those lawyers get a cut of Ven-ACare's whistleblower awards, of course.
But, Breen said, his aggressive approach
helps the government recover more
money. And it means a bigger cut for
Ven-A-Care. "The assistance provided
by the relator and their counsel team is
--
-..- -- - - - - - - - - - - - - - - - ------- --------
.
-
"183""3.1 Iii
"liM hiNi I
5421 .2 million
Yen-A.(are award
$88.4 million
Ven-A-ure award
$25 million
VEN·A·CARE, FROMPAGE 4
--
Setttement
$169 million
Setttemont
$515 million
Ytn-A-(are award
$25 million
Abbon Laboratories Inc.. B. Braun Medicalll1C. and
Roxane Laboratories Inc. (Boehringer Ingelheim Roxane Inc.)
Teva Pharmaceuticals Inc.
s.ttItment
Iii. 'i"@!li
Mylan Pharmaceuticals, UDl Laboratories, AstraZeneca
Pharmaceuticals and Ortha-McNeil Pharmaceutical
Bristol-Myers Squibb
Settlement
532 million
- - - - - - - - - - - - -- - - - - -- - - - -- - - - - - - - ---- - - .... - - - - - - - - - - - - - -
------ -- - --- - ------ -- - - ---~
"
Ven-A-care award
526 million
$44.8 million
...
Actavis Mid-AtlantiC and Actavls Elizabeth
Settlement
$1703 million
Yen-A-Care award
Not yet determined
always a key factor in the relator share,
and it certainly has been in our cases,"
he said.
Ven-A-Care's approach was on display
in the drug-pricing trial against the generic drug maker Actavis that wrapped up
early this month in Austin. Along with
Breen, Ven-A-Care had a haH-dozen lawyers at the trial. And Breen said they tried
the case with the state's lawyers as a single team. "U you saw us in the courtroom,
unless we made an appearance on the
record you would not be able to determine who worked for whom," he said.
A judge must still enter a final judgment on the jury's $170 million verdict,
and Ven-A-Care's share of the verdict
hasn' t been determined. Breen said
he typically doesn't bother fighting for
maximum relalOr shares in Ven-A-Care's
cases: There are so many, and Ven-ACare tends to get close to the maximum
anyway. For Breen and his only client,
the Ven-A· Care litigation just marches
on.
David Bario can be contacted at dbario@alm .com.
Registration is complimentary - sign up today!
• Earn Free CLE Credits*
• Attend seminars and
panel discussions in real
time in the "virtual"
auditorium
• Visit booths and
download brochures
• Interact with colleagues
through chat
• Win prizes!
The Exhibit Halls are
open 2417365!
For sponsorship opportunities contact Henry Dicker at 212-457-7902 or email hdicker@alm.com
-Terms end conditions sppIy. See website for details.
I'M§:, . 1RON~-
e'lexisNexis'
-DfEGiS
.- .-
NEXTpage"
An ALM Even!